Changes at Relypsa, Genzyme, Benitec, Genmab, Celsion, Alligator Bioscience – People on the move
Claire Lockey has been named vice president, regulatory affairs at Relypsa. Lockey will oversee a number of areas, including quality assurance. Before joining Relypsa Lockey worked at Fibrogen, Titan Pharmaceuticals, Layton Bioscience and Connetics.
All 10 current members of the Genzyme board of directors have been re-elected at the annual meeting of shareholders. Genzyme also appointed Dennis Fenton, settling the dispute with Relational Investors, as well as Steven Burakoff and Eric Ende, at the request of Carl Icahn.
Benitec has appointed Peter French as CEO. French joined Benitec in August 2009 as chief scientific officer and has previously worked at Cryosite, Probiomics and Fermiscan.
Lisa Drakeman has retired as CEO of Genmab. Jan van de Winkel, the company’s former chief scientific officer, will replace Drakeman, who has also stepped down from the board of directors. Van de Winkel co-founded Genmab and has also worked at Medarex Europe.
Celsion has named Jeffrey Church as VP and chief financial officer. Church has previously worked as chief financial officer at Alba Therapeutics, Novavax, GenVec and Meridian Medical Technologies.
Sibylle Lenz has joined Alligator Bioscience as CEO. Earlier in her career Lenz worked at Dako and H Lunbeck.
